Market Cap 574.24B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.31
Forward PE 21.06
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 8,771,100
Avg Vol 8,443,632
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 56%
Beta 0.34
Analysts Strong Sell
Price Target $243.16

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
NasdaqPulse
NasdaqPulse Apr. 9 at 2:46 PM
Market Watch - Key Moves Today 👉Click to view @NasdaqPulse for timely updates amid the volatility. $AAPL showing some serious weakness today, down -0.58% and -0.63%. Looks like selling pressure is building. On the flip side, $JNJ is holding strong with a +0.42% gain. This one's showing resilience despite the broader market mood. The macro context is heavy right now — delays in big tech projects and broader sentiment issues are dragging things down. It's clear investors are cautious, especially in the tech space. Keep an eye on $AAPL for further signs of weakness, while $JNJ might continue to outperform in the current environment.
0 ¡ Reply
1986iamwallstreet
1986iamwallstreet Apr. 9 at 2:34 PM
$JNJ go ahead and make the purchase of $MDGL for 20 billion
0 ¡ Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 1:13 PM
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value $NGTF $NVDA $JNJ $AMZN $TSLA https://ibn.fm/16tH7
0 ¡ Reply
sblack9k
sblack9k Apr. 9 at 12:13 PM
0 ¡ Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 12:12 PM
$JNJ not exciting, just reliable - and that’s enough
0 ¡ Reply
frb1985
frb1985 Apr. 9 at 10:58 AM
$JNJ wait. What. LOL
0 ¡ Reply
frb1985
frb1985 Apr. 9 at 10:57 AM
$JNJ wait what. LOL
0 ¡ Reply
DragonAlgo
DragonAlgo Apr. 9 at 7:43 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $1.13 Stop: $0.81 TP1: $1.47 TP2: $1.92 TP3: $2.71 Momentum tape remains active. 🔗 https://dragonalgo.com
0 ¡ Reply
profitscout8
profitscout8 Apr. 9 at 7:41 AM
$JNJ The breakup with Kenvue has made J&J a pure-play pharma and med-tech powerhouse. The legal overhangs are finally being settled. It's a AAA-rated balance sheet—one of the few left in the world. I love the stability here. The dividend increase streak is legendary. This is a cornerstone of my portfolio for a reason. Buying the consolidation.
0 ¡ Reply
SenefAS
SenefAS Apr. 9 at 7:22 AM
$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE
0 ¡ Reply
Latest News on JNJ
The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 20 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX


US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 22 days ago

US FDA approves J&J's oral psoriasis pill


US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 4 weeks ago

US FDA approves JNJ's blood cancer drug


Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 6 weeks ago

Does JNJ Stock Still Offer Value?


Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 6 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech


After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 13, 2026, 7:00 AM EST - 7 weeks ago

After A 55% Surge, Is JNJ Stock Still A Buy?


The Big 3: JNJ, XOM, KO

Feb 5, 2026, 1:00 PM EST - 2 months ago

The Big 3: JNJ, XOM, KO

XOM KO


What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 8:47 AM EST - 2 months ago

What's Behind The 50% Surge In JNJ Stock?


This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

Jan 29, 2026, 12:42 PM EST - 2 months ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW


NasdaqPulse
NasdaqPulse Apr. 9 at 2:46 PM
Market Watch - Key Moves Today 👉Click to view @NasdaqPulse for timely updates amid the volatility. $AAPL showing some serious weakness today, down -0.58% and -0.63%. Looks like selling pressure is building. On the flip side, $JNJ is holding strong with a +0.42% gain. This one's showing resilience despite the broader market mood. The macro context is heavy right now — delays in big tech projects and broader sentiment issues are dragging things down. It's clear investors are cautious, especially in the tech space. Keep an eye on $AAPL for further signs of weakness, while $JNJ might continue to outperform in the current environment.
0 ¡ Reply
1986iamwallstreet
1986iamwallstreet Apr. 9 at 2:34 PM
$JNJ go ahead and make the purchase of $MDGL for 20 billion
0 ¡ Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 1:13 PM
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value $NGTF $NVDA $JNJ $AMZN $TSLA https://ibn.fm/16tH7
0 ¡ Reply
sblack9k
sblack9k Apr. 9 at 12:13 PM
0 ¡ Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 12:12 PM
$JNJ not exciting, just reliable - and that’s enough
0 ¡ Reply
frb1985
frb1985 Apr. 9 at 10:58 AM
$JNJ wait. What. LOL
0 ¡ Reply
frb1985
frb1985 Apr. 9 at 10:57 AM
$JNJ wait what. LOL
0 ¡ Reply
DragonAlgo
DragonAlgo Apr. 9 at 7:43 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $1.13 Stop: $0.81 TP1: $1.47 TP2: $1.92 TP3: $2.71 Momentum tape remains active. 🔗 https://dragonalgo.com
0 ¡ Reply
profitscout8
profitscout8 Apr. 9 at 7:41 AM
$JNJ The breakup with Kenvue has made J&J a pure-play pharma and med-tech powerhouse. The legal overhangs are finally being settled. It's a AAA-rated balance sheet—one of the few left in the world. I love the stability here. The dividend increase streak is legendary. This is a cornerstone of my portfolio for a reason. Buying the consolidation.
0 ¡ Reply
SenefAS
SenefAS Apr. 9 at 7:22 AM
$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE
0 ¡ Reply
Digitalization2026
Digitalization2026 Apr. 8 at 11:41 PM
$SRXH 🏆 Beating the S&P 500 while most stocks fell is a big deal — that’s real performance, not noise 📈 What a lot of people miss: the dividend talk is HUGE. If SRXH starts returning cash to holders, you earn money just for holding, on top of share price gains 💰 Look at top dividend stocks for perspective: • Johnson & Johnson pays ~3.5% annually • Exxon Mobil ~3.8% • Apple ~0.6% If SRXH ever pays a meaningful yield tied to profits, that’s extra return beyond capital appreciation. Also worth noting: SRXH chose not to enact a reverse split recently — that reduces dilution overhang and signals management prefers organic price discovery over a cosmetic split that doesn’t change fundamentals. Beating the market + possible dividends + reduced overhang = a narrative most haven’t priced in 🚀 Not financial advice ⚠️ $JNJ $AAPL $XOM $SPY https://www.emjx.ai
1 ¡ Reply
The__short_squeezer
The__short_squeezer Apr. 8 at 9:03 PM
$WMT $ORCL $MU $SNDK $JNJ I was partially right. Even though the regime has not fallen (but I believe it will eventually fall through a civilian process), Trump and certainly Netanyahu will not do this stupid thing of continuing the war for the long term. Now is the time for the market to calm down and reach new heights. Trump and Netanyahu have proven that they are responsible leaders!
3 ¡ Reply
TechTraderGrok
TechTraderGrok Apr. 8 at 8:19 PM
Bought $JNJ at $240.84. From Grok: "JNJ looks attractive for a long here with bullish analyst notes targeting $250, solid pipeline momentum, and constructive longer-term uptrend ahead of earnings. " https://www.techtrader.ai/grokwall/?post=17637&utm_source=dlvr.it&utm_medium=stocktwits
0 ¡ Reply
trenddetector
trenddetector Apr. 8 at 6:37 PM
$JNJ Made some updates here. Please share with those in need! "Your path through cancer's complexity. Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention — all in plain English, all in one place. Browse anonymously. No account required.” https://nimble-frangollo-81ff5e.netlify.app/#
0 ¡ Reply
IN0V8
IN0V8 Apr. 8 at 2:55 PM
$JNJ Opportunity Citigroup raises target price to $285 from $274
0 ¡ Reply
DragonAlgo
DragonAlgo Apr. 8 at 2:04 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $260.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 🔗 https://dragonalgo.com
0 ¡ Reply
KarenLouisa
KarenLouisa Apr. 8 at 1:42 PM
POLITICAL PORTFOLIO FLOW ALERT Rep. Lloyd Doggett (TX-37) just filed a new disclosure — and the flow is steady, not speculative. These are mostly automatic dividend reinvestments, but the names matter Buys: • $HD – Home Depot (03/26/2026) • $IBM – IBM (03/10/2026) • $JNJ – Johnson & Johnson (03/10/2026) • $PPG – PPG Industries (03/12/2026) What this signals: • Continued accumulation in dividend + blue-chip leaders • Exposure to healthcare ($JNJ), tech/services ($IBM), and cyclical economy plays ($HD, $PPG) • Positions align with sectors tied to tax policy, trade, and economic oversight Key takeaway: This isn’t aggressive trading — it’s consistent long-term capital allocation into cash-flow heavy giants. These names are often seen as “policy-sensitive” and macro-resilient. Smart money or just auto-reinvesting? Either way, these flows don’t go unnoticed… watch how $HD $IBM $JNJ $PPG behave next.
0 ¡ Reply
Wallstfan
Wallstfan Apr. 8 at 1:41 PM
$JNJ added on the dip
0 ¡ Reply
NasdaqPulse
NasdaqPulse Apr. 8 at 1:26 PM
$JNJ quietly setting up while the market chases higher-beta names. 👉Click to view @NasdaqPulse for timely updates amid the volatility. This isn’t a hype ticker — it’s a capital preservation + steady growth compounder with a global moat. When volatility spikes, money tends to rotate back into names like this for stability, dividends, and defensive positioning. Price action is coiling… compression often precedes expansion. If we see a breakout with volume, it could mark a shift in institutional positioning. If not, it remains a slow-burn accumulation zone. Boring? Maybe. Powerful over time? Historically, yes. Watching for confirmation — not forcing the trade.
0 ¡ Reply
GordoHLYK13
GordoHLYK13 Apr. 8 at 1:12 PM
$ABBV $CUE $JNJ I meant to say please read Btw This news isn’t just a headline — it’s structured upside with real future cash flow potential. If the stock holds its gains after 9:30 with strong volume, that’s when institutions and smarter money typically show up and validate the move. 🚀
0 ¡ Reply
RobinCollins1
RobinCollins1 Apr. 8 at 1:08 PM
$BRK.B $JPM $XOM $JNJ $KO This is Richard Bernstein’s playbook for a slower, more volatile market — and it’s all about defense + cash flow dominance. 🔹 $BRK.B — sitting on ~$200B+ in cash, essentially a fortress when risk assets wobble. 🔹 $JPM — the most resilient mega-bank, still throwing off massive earnings + dividends even in a slowdown. 🔹 $XOM — energy hedge + inflation protection. When oil spikes, cash flow follows. 🔹 $JNJ — healthcare stability + decades of dividend growth = pure defensive alpha. 🔹 $KO — the classic “sleep-well-at-night” stock. 60+ years of dividend hikes. Bernstein’s message is simple: when markets get shaky, own cash flows, not narratives. If growth rolls over, this basket doesn’t just protect — it outperforms.
0 ¡ Reply
GordoHLYK13
GordoHLYK13 Apr. 8 at 12:33 PM
$CUE please PR CUE just laid out a path to $337M+ in milestones plus royalties—that’s not hope, that’s a structured upside pipeline. Big pharma doesn’t write checks like that unless they see real potential. If they keep hitting milestones, this isn’t just a trade—it’s a multi-stage re-rating story waiting to unfold. 🚀 $JNJ $ABBV
0 ¡ Reply